

PRODUCT DATASHEET

ChemiScreen™ β₃ Adrenergic Receptor Membrane Preparation

CATALOG NUMBER: HTS159M QUANTITY: 200 units

LOT NUMBER: SC384996 VOLUME/CONCENTRATION: 1 mL, 2 mg/mL

BACKGROUND: The beta adrenergic receptors mediate the effects of endogenous catecholamines, such as

epinephrine, by coupling to G_s to stimulate cAMP. Whereas β_1 and β_2 are found predominantly in heart, the β_3 receptor is found primarily in adipose tissue. Activation of adipose β_3 results in lipolysis and thermogenesis. A polymorphism in the human gene for β_3 is associated with weight gain in obese patients (Clement *et al.*, 1995). In addition, mice lacking the β_3 -adrenoceptor display increased total body fat, particularly on a high fat diet (Revelli *et al.*, 1997). These observations indicate that β_3 is a possible target for obesity treatments. The β_3 adrenoceptor membrane preparations are crude membrane preparations made from our proprietary stable recombinant cell lines to ensure high-level of GPCR surface expression. Thus, they are ideal HTS tools for screening of antagonists of β_3

adrenoceptor interactions.

APPLICATIONS: Radioligand Binding Assay




Figure 1. Saturation Binding for β₃ receptor. 10 μg/well β₃ Adrenoceptor Membrane Preparation was incubated with increasing amount of [125 I]-(-)ICYP in the absence (total binding, TB) or presence (nonspecific binding, NSB) of 200-fold excess unlabeled SR59230A. Specific binding (SB) was determined by subtracting NSB from TB. The data are from a representative sample from lot SC384996.



Discovery Services




Figure 2. Competition Binding for β_3 adrenoceptor. β_3 adrenoceptor Membrane Preparation (10µg/well) or Wild-Type Chem-1 membrane preparation were incubated with 0.75 nM | 125|-(-)ICYP and increasing concentrations of unlabeled SR59230A, and more than an 8-fold signal:background was obtained. The data are from a representative sample from lot SC384996.

SPECIFICATIONS: 1 unit = 10 µg

 B_{max} for $[^{125}I]$ -(-)lodocyanopindolol binding: 1.32 pmol/mg protein K_d for $[^{125}I]$ -(-)lodocyanopindolol binding: 0.65 nM

Signal:background: >8-fold

Species: Full-length human ADRB3 cDNA encoding the β₃ adrenoceptor (Accession

number NM 000025)

HOST CELLS: Chem-1, an adherent mammalian cell line without any endogenous

expression of β₃ adrenergic receptor.

RECOMMENDED ASSAY CONDITIONS: Membranes are mixed with radioactive ligand and unlabeled competitor (see Figures 1 and 2 for concentrations tested) in binding buffer in a non-binding 96-well plate, and incubated for 2 h. Prior to filtration, an FC 96-well harvest plate is coated with 0.33% polyethyleneimine for 30 min, then washed with 50 mM HEPES, pH 7.4. The Binding reactions are transferred to the filter plate, and washed 3 times (1 mL per well per wash) with Wash Buffer. The wells are then dried and counted.

Binding buffer: 50 mM HEPES, pH 7.4, 5 mM MgCl₂, 1 mM CaCl₂, filtered and stored at

Radioligand: [125]-(-)lodocyanopindolol (PerkinElmer # NEX189)

Wash Buffer: 50 mM HEPES, pH 7.4, 500 mM NaCl, filtered and stored at 4°C.

One package contains enough membranes for at least 200 assays (units), where a unit is the amount of membrane that will yield greater than an 8-fold signal:background ratio with [¹²⁵I]-(-)lodocyanopindolol at 0.75 nM.

PRESENTATION:

Liquid in packaging buffer: 50 mM Tris, pH 7.4, 10% glycerol, and 1% BSA with no preservatives.

Packaging method: Membrane proteins were adjusted to the indicated concentration in packaging buffer, rapidly frozen, and stored at -80°C.



STORAGE/HANDLING:

Store at -70°C. Product is stable for at least 6 months from the date of receipt when stored as directed. Avoid repeated freeze/thaw cycles.

REFERENCES:

- 1. Clement K *et al.* (1995). Genetic variation in the beta3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. *N. Engl. J. Med.* 333:352-354.
- 2. Revelli JP *et al.* (1997). Targeted gene disruption reveals a leptin-independent role for the mouse beta3-adrenoceptor in the regulation of body composition. *J. Clin. Invest.* 100:1098-1106.

FOR RESEARCH USE ONLY; NOT FOR USE IN DIAGNOSTIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

No part of these works may be reproduced in any form without permission in writing.

Eurofins Pharma Bioanalytics Services US Inc. is an independent member of Eurofins Discovery Services.